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Background. Extensive work in basic and clinical science suggests that biological mechanisms of 
aging are causally related to the development of disease and disability in late life. Modulation of 
the biological mechanisms of aging can extend both lifespan and health span in animal models, 
but translation to humans has been slow.  
 
Methods: Summary of workshop proceedings from the 2018-19 Epidemiology of Aging 
Workshop hosted by the Intramural Research Program at the National Institute on Aging. 
 
Results: Epidemiologic studies play a vital role to progress in this field, particularly in evaluating 
new risk factors and measures of biologic aging that may influence health span, as well as 
developing relevant outcome measures that are robust and relevant for older individuals.  
 
Conclusions: Appropriately designed epidemiological studies are needed to identify targets for 
intervention and to inform study design and sample size estimates for future clinical trials 
designed to promote healthspan.  
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The successes of medical therapy, preventive medicine, and public health have resulted in 
unprecedented increases in the numbers of individuals reaching old age. Although the health of 
older adults may be improving, the even greater rise in longevity has resulted in expansion in the 
absolute number of older persons affected by multiple chronic diseases and disabilities. These 
demographic trends are outstripping gains in health, with greater numbers of older people in 
need of major, often costly, medical and surgical treatments and long-term care (1). Thus, 
identification and amelioration of modifiable factors (e.g., following a healthy diet, not smoking, 
regular physical activity, and avoidance of environmental stresses) that could help to compress 
morbidity and increase health span is a public health priority more urgent than ever before. 
 
A new generation of studies is addressing the underlying biology of the aging process in the hope 
of identifying new targets for interventions that could increase health span. This concept has 
broad appeal but its translation to care is more complex than is commonly appreciated. 
Currently, we do not know the best and most efficient approaches to define and operationalize 
health span, which is a necessary requirement in identifying pathways, dimensions, and/or risk 
factors that could be targeted for its expansion. Health span studies focusing on individual 
diseases fail to address geriatric syndromes, such as delirium, sarcopenia, and incontinence, as 
well as changes in physical and cognitive function. Hence, the science of designing clinical trials 
that target health span expansion is still in its early stages.  
 
New approaches in the epidemiology field are addressing the issue of adequately measuring and 
defining health span. Global biomarkers of phenotypical and biological aging have been 
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developed by combining health dimensions captured in large epidemiological studies using 
existing or new biological measures performed on biorepository specimens (2-4). These efforts 
have demonstrated that single or aggregate biomarkers/indices of global susceptibility to disease 
can predict the risk of impending deterioration of health status and multimorbidity, dimensions 
that can be directly connected to health span. Although these methods require refinement, 
especially validation from a longitudinal perspective, the preliminary results suggest that using 
these tools in future epidemiological studies may facilitate in identifying mechanisms that can be 
targeted by clinical or population-based intervention trials aimed at expanding health span before 
physiologic reserve has been exhausted. (Figure 1)  
 
Are there innovative designs for epidemiologic studies that can maximize the effectiveness of 
clinical or population-based intervention trials in measuring aging outcomes? What outcomes are 
most relevant and impactful to aging populations? Are there new approaches to assessing risk? 
These questions were recently discussed in workshop organized in Baltimore by the Intramural 
Research Program of the National Institute on Aging. This manuscript is an attempt to 




Life course approach 
The course of aging is the product of many life events and exposures, which begin as early as 
conception, however, many epidemiologic studies of aging only begin in old age. The rare 
cohorts that have been followed from birth to old age are starting to reveal trajectories of health 
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dimensions and critical time points in those trajectories that can guide potential preventive 
interventions earlier in the aging process (5, 6). The availability of biological samples from these 
cohorts is even more limited revealing an important scientific gap that should be addressed in 
future studies. According to the theory of developmental origins of health and disease 
(DOHAD), experiences in early life modulate physiological changes that condition health 
trajectories later in life, but the biological mechanisms that sense these inputs and encode them 
into epigenetic modifications that cause persistent shifts in the cellular composition of tissues are 
unknown. Knowledge about these mechanisms would be highly translatable to clinical 
applications and public health policy. A life course approach can be added into existing cohorts 
using proxy measures of early life exposures, such as the North American Adult Reading Test 
(NART) to measure premorbid IQ (7), electronic health records to obtain past medical history, or 
geocoding of the environment from early life home address (8, 9). Combinations of cohorts of 
various ages have also been put together to create synthetic or “knitted” cohorts, revealing a life 
course perspective (10). Early life exposures, such as birth weight and educational attainment, 
should be examined not only as life course exposures but also as stratification variables to assess 
interactions with current exposures (11). For example, the association of BMI with mortality in 
old age depends on the life trajectory of weight change (12), while the benefits of lowering blood 
pressure could vary based on when in the life course the blood pressure was measured (13).  
 
Big Data 
The trend towards mega-data comes with the hope that larger, simpler study designs that 
leverage existing clinical data will be more cost-effective and efficient in identifying both 
exposures and outcomes. Large datasets have been assembled using administrative records, 
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electronic health records, and/or combined cohort studies. Several advantages relevant to aging 
studies have been documented. For example, large electronic health record (EHR) databases 
have allowed for infrequent events, such as delirium (14), to be identified in larger numbers and 
studied with adequate power, although validation work suggests that sensitivity and specificity 
are limited in many situations (15). A major disadvantage to EHR-based studies is the lack of 
unbiased, reliable assessments of physical and cognitive performance, geriatric syndromes, and 
common symptoms (e.g., pain, fatigue, and sleep disorders) in clinical settings. For these 
important issues in aging, planned cohort studies remain the best option. However, records may 
include long-term follow-up (>10 years), allowing the latency period for many chronic diseases 
to be revealed. For example, obesity may be a risk factor for dementia in the long-term, but is 
confounded by weight loss caused by the developing dementia pathology when examined in the 
shorter term (16).  
 
Studies conducted in mega-cohorts (e.g., the UK Biobank) and in consortia of cohorts have 
demonstrated that large sample sizes are required to identify genetic variants that have very small 
effects on health. Association studies looking at traditional risk factors provide dubious results 
because of the lingering possibility of reverse causation and confounding. Instead, genetic 
polymorphisms already present at birth can provide near-causal estimates of association between 
variants and outcomes (17). For example, hemochromatosis C282Y homozygotes experience 
greater penetrance to clinical disease and symptoms than previously recognized when better-
powered assessments are performed using a more prospective design, as well as when older 
groups are included (14, 18). 
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A clear advantage of using a mega-cohort is that studies that examine associations of interest 
within and across pre-defined strata of the population have a sufficient sample size to compute 
reliable estimates and interactions between stratification and exposure variables. For example, a 
recent mega-cohort study revealed that hypertension treatment appears maximally effective at 
young age and diminishes in effectiveness for cardiovascular disease protection with older age, 
although these treatments benefit even the oldest old (19). However, there is usually a trade-off 
between having a large sample size and the quality of the data collected and the choice may 
depend on the scientific question to be addressed. Access to clinical tests, imaging, and 
electronic record data will assist in developing clinically valid prediction models and support 
software development to alert clinicians to potentially actionable factors, aiding in translation of 
research to practical applications.  
 
Deep Phenotyping 
New methods in imaging, personal monitoring, and cellular/tissue isolation techniques are 
constantly being developed and could uncover previously uncharacterized mechanisms, as well 
as novel intervention targets. Such methods should be carefully assessed for longitudinal 
reproducibility. Some biobank studies are linked to existing clinical information, but health 
records usually do not include important information defining the health and function of older 
adults and biobanked material may not be appropriate for new hypotheses. Dementia studies 
benefit from the availability of neuroimaging data, including recent quantification of amyloid 
and tau protein in the brain, as well as specific brain and other tissue biomarkers—including 
blood and CSF exosomes—and a detailed assessment of type, severity, and longitudinal 
emergence of cognitive and non-cognitive symptoms. Recent evidence indicates that different 
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types of dementia can be distinguished by longitudinal patterns of symptom development that are 
generally not accurately ascertained using routine health records, suggesting that standardizing 
the data collected in medical records, as is performed currently in large epidemiologic cohort 
studies, may improve the quality of research using medical records (20). 
 
New observational studies and clinical trials must be forward-thinking when collecting 
biological samples, cognizant of emerging technology, and that many of the new generation 
biomarkers will require specialized isolation and storage of cells/tissues. For example, an 
emerging frontier in the study of biomarkers is the use of “liquid biopsies” that use extracellular 
vesicles, which could be particularly valuable to discriminate between biomarkers coming from 
different tissues (21). Extracellular vesicles can be isolated from frozen blood samples, although 
there is limited information on whether long-term storage or repeated cycles of thawing and 
freezing affect their informational content. In contrast, isolating small numbers of hematopoietic 
stem cells or producing induced pluripotent stem cells is best performed using freshly collected 
samples. Assessments that examine proteomics, metabolomics, gene expression, and circulating 
nucleic acids are additional examples of methods that are optimally effective when samples are 
collected and stored according to specific, dedicated protocols. 
 
Clinical Trials 
Advances in aging biology suggests that aging itself is more modifiable than traditionally 
thought. Preventive interventions that target biological aging are being tested in humans (e.g., 
rapamycin (22), metformin (23), canakinumab (24), caloric restriction (25)), although generally 
on a small scale. If the intervention requires sustained treatment over life, then the effects of 
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these interventions cannot easily be evaluated for longevity—the most direct biomarker of 
biological aging—as this would require decades of follow-up. However, some types of 
interventions, such as senolytic therapy, may require shorter follow-up to demonstrate effects on 
health span. Surrogate biomarkers of biological and phenotypic aging are a main focus of current 
research but have not been fully developed for human studies. Ideally, interventions aimed at 
maximizing health span should be able to modify one or more of the hypothetical biological 
mechanisms of aging, and the effectiveness of these therapies should be evaluated by objective 
health outcomes that are anchored to perceived clinical improvement. Inclusion of assessments 
that are practical for clinical settings should be considered when designing epidemiologic studies 
to best enable translation from epidemiology to clinical trials. Ultimately this approach would 
translate to more rapidly to clinical practices that directly address the underlying causes of aging 
(26). 
 
Epidemiologic research has played a key role in the pathway to clinical trial conceptualization 
and design. Isolated systolic hypertension was first identified as a major risk factor for stroke in 
the Framingham cohort (27). This led to the proposal for the Systolic Hypertension in the Elderly 
Program trial that examined antihypertensive therapy targeting of isolated systolic hypertension, 
which demonstrated a reduction in stroke (28) but did not show benefit for dementia or 
disability, potentially due to differential drop out (29). Study designs have since evolved to 
include follow-up in home or nursing home settings, as well as detailed proxy assessment 
protocols. 
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Several observational studies had identified low physical activity as a modifiable risk factor and 
mobility disability as a common outcome. Planned using these observations, the LIFE clinical 
trial was conducted to increase walking, successfully reducing mobility disability in study 
participants (30). Simulated from existing studies, the population at risk was defined using the 
Short Physical Portable Performance Battery developed in the Established Populations for 
Epidemiologic Studies of the Elderly cohort (31). In this cohort, individuals were also at high 
risk for multimorbidity, which was a challenge for maintaining the interventions and complicated 
the follow-up (32). Better estimates of such competing risks for multimorbidity are needed for 
future trial planning.  
 
Cohort studies that utilize repeated measurements of specific biomarkers are essential for 
providing estimates of expected changes that might be seen in trial participants. In particular, 
cohort studies also provide data about the variability (i.e., the standard deviation in the 
population and the variability within individuals) of these markers, which is essential in planning 
sample sizes for trials that use changes in a biomarker as the primary endpoint. Furthermore the 
variability per se may be a valuable predictor, e.g. blood pressure variability predicts vascular 
risk over and above mean blood pressure perhaps serving as a proxy for arterial stiffness (33).  
 
Diversity and Birth Cohorts 
The US population is increasingly diverse, with increases in racial and ethnic groups being most 
dramatic in the oldest old. Subgroups may vary in risk for disease, disability, or dementia and 
may be exposed to unique environmental and genetic risk factors that influence their aging. 
Globally, aging is most rapid in less developed countries, providing opportunities to observe the 
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impact of social changes on aging in a shorter time period. In the US, diverse cohorts recruited 
for studying specific diseases in early-to-midlife should be followed to understand their aging 
outcomes. Studies of the oldest old are especially needed, thus researchers should not apply an 
upper age limit in aging research, a view consistent with a new NIH policy that requires 
justification for not including older adults in relevant research (34, 35). 
 
A central question remains: Is aging changing over time? A challenge to epidemiologic studies 
of aging is the lack of a solid method for distinguishing between birth cohort effects and secular 
trends. Vast differences exist between previously studied cohorts and more recent cohorts based 
largely on societal changes, which could translate into major differences in disease and disability 
in late life. For example, more recent birth cohorts have higher caloric intake, lower levels of 
activity, and greater obesity than earlier birth cohorts. They also have later exposure to common 
viruses and more frequent exposure to antibiotic therapy. The extent to which these differences 
will translate to greater or lesser disease and disability in old age is still uncertain. 
 
Outcomes 
The quality of the remaining years of life is the ultimate measure of success in improving aging 
outcomes. An older adult’s perception of the quality of life is based on individual, personal 
priorities. Patient-reported outcomes usually refer to these perceptions, which are assessed by 
self-report of overall health, specific symptoms, or perceived satisfaction and quality of life (36). 
These outcomes complement other common age-oriented outcomes, such as multimorbidity, 
geriatric syndromes, and disability. 
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Epidemiologic research has traditionally considered multimorbidity, geriatric syndromes, and 
types of disability as important outcomes. Conceptually, multimorbidity is a summary of the 
total number of conditions affecting a person, whereas co-morbidity assumes a disease-centered 
focus regarding a primary condition of interest with consideration for additional conditions (37). 
Multimorbidity can include conditions that are linked pathophysiologically or have underlying 
risk factors in common—such as “cardiovascular morbidity”, which encompasses myocardial 
infarction, stroke, and heart failure—or diabetes, hypertension, and arthritis in obese people. It 
can also include conditions that are unrelated in pathogenesis or management (38). A recent NIA 
conference on multimorbidity proposed that research priorities to accomplish progress in this 
field include: standardizing the universe of morbidity to be included in practical tools, deciding 
how to weight conditions and for which outcomes, determining if information on duration and 
severity should be considered in diagnosis, highlighting opportunities and limitations of 
electronic health records, and innovating standard and new analytic techniques (39). 
Accumulation of multimorbidity appears to be a fundamental feature of the aging process, thus, 
the accumulation rate has been proposed to be a composite endpoint of interventions that target 
aging (40). This outcome has gained some traction with many stakeholders as a global measure 
of the aging process. 
 
Geriatric Syndromes 
Geriatric syndromes are often either included as multimorbid conditions or examined as distinct 
outcomes/phenotypes. They are by definition highly multifactorial, with interacting pathogenic 
etiologies and mechanisms (41). Common geriatric syndromes—such as incontinence, delirium, 
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frailty, or falls—are not always assessed in administrative data or epidemiologic studies. These 
syndromes may be assessed differently from one study to the next and, if assessed, risk factor 
assessment may also vary. For example, emerging evidence suggests that influenza is a major 
risk factor for both catastrophic and progressive disability (42), yet information regarding both 
influenza infection and muscle performance are rarely available in the same dataset. Some 
multifactorial syndromes, such as delirium, may be limited to inpatient records and are not 
assessed with standard methods. Accessing information from large electronic health records has 
the potential to capture infrequent events, such as delirium, with high specificity but low 
sensitivity (43). Frailty has been conceptualized as a geriatric syndrome with a defined set of 
signs and symptoms (phenotype), but also as an index of accumulated deficits, similar to 
multimorbidity (44, 45). Frailty, whether assessed in trials as a syndrome or as an index of 
deficits, has been useful as an outcome in clinical trials. (46, 47).  
 
Disability and Function 
Health span can also be characterized as disability-free survival. Disability endpoints include 
loss of ability to perform activities of daily living, loss of independence or active life expectancy, 
or loss of mobility. In older adults, disability is often linked to disease and is progressive in 
contrast to earlier onset disability, which is often more fixed. Consequences of disability include 
loss of social engagement and increased cost of assistance or care. Overall survival has increased 
more rapidly than survival free of disability, especially in men, although years with severe 
disability seem stable (48). Harmonized measures of health, such as the Patient-Reported 
Outcomes Measurement Information System, provide methods for patient-reported outcomes of 
physical function, as well as psychological and social function. Unfortunately, there is no one 
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standard assessment of disability that fits all purposes at present, and conceptual frameworks 
have been shifting. The Nagi model, which is most often used in the aging literature, 
distinguishes impairments or limitations in functions and disabilities as distinct constructs, but 
does not address social participation and environmental context, which are features of the 
International Classification of Functioning, Disability, and Health model (49). Severity is 
sometimes captured by reported degree of difficulty, but scales can vary (50). Finally, 
fluctuations in function illustrate that late-life disability is a dynamic process (51).  
 
Regardless of methodology, the loss of function with age appears to be an index of the aging 
process itself. Gait speed and grip strength are remarkably robust in their ability to capture 
change over time, which lends them to be usefully translated as intermediate outcomes in clinical 
trials. In recent clinical trials, disability outcomes have been defined by either self-report or 
performance, such as reduction in ability to walk 400 meters to operationalize mobility disability 
(52). Meaningful changes in performance have been defined by anchoring change to self-
reported improvement or worsening in function (53). Standardization of both self-report and 
performance measures within a conceptual framework should be applied to epidemiologic 





Low physical activity is an important risk factor for morbidity and mortality in older adults and 
is also an indicator of functional capacity. Self-reported physical activity is subject to bias and 
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does not capture low levels of activity, but self-report adds a valuable subjective dimension to 
personal activity monitoring (54). Accelerometry uses sensors to detect acceleration in three 
planes and provides raw activity counts over days to weeks, which can be summarized as 
duration, intensity, and frequency. More recently, patterns of activity across the day have 
indicated that older adults have a lower total volume of activity that tends to decrease earlier in 
the day in comparison to younger adults (55). This earlier reduction in volume is associated with 
perceived fatigability. Additional information on activity behavior can be gathered by studying 
patterns of peak activity that vary in groups characterized by different balance performance, as 
well as frequency and type of fall (56, 57). With advanced age and frailty, bouts of activity are 
shorter and increasingly fragmented and can predict higher mortality risk. In randomized 
controlled trials, increased walking lead to increased physical activity and reduced risk of 
disability (30), but these behaviors are challenging to sustain. New questions address if sedentary 
time and low levels of activity are distinct risk factors that require specific interventions, as well 
as whether low activity is a marker of an early stage in the path to disability. Stratification of 
patients based on patterns of activity may be useful in order to better identify appropriate 
populations and targets for intervention. 
 
Nutrition 
Epidemiologic studies have helped to identify important health, environmental, and social factors 
that affect nutrient intake, absorption, and metabolism. Observational dietary assessment has 
been used to self-report the intake of specific foods or frequency of intake of various food 
groups. Blood biomarkers of specific nutrients can supplement these assessments, as previously 
reported in assessing vitamin D intake and metabolism (58). Metabolomic profiles may also be 
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used to monitor useful biomarkers for assessing diet and nutritional interventions. Several trials 
have demonstrated different metabolomic biomarker patterns that can distinguish between types 
of diet (59, 60), although they do not always have the necessary sensitivity or specificity. Some 
metabolites can also reflect short-term intakes, medication effects, or intermediate metabolism 
by gut microbiota (61), but few existing epidemiologic studies of aging have incorporated 
microbiome and metabolomics assessments (62). There have been attempts to better quantify 
dietary intake using smart phone applications, but these have yet to be established as superior to 
standard approaches, such as food frequency or food diaries (63). New approaches to assessing 
diet and nutrition hold promise in better informing targets for intervention in older adults (64).  
 
Social Factors 
The interplay between social factors and health in old age is substantial. Social factors can 
influence activity and diet, reduce accessibility to resources needed to improve health, or directly 
impact biological status. Adverse socio-economic experience across an individual’s life course 
influences subsequent health outcomes (65), which can then adversely impact social activity and 
relationships later in life. Epidemiologic studies of older adults can be used to assess historical 
factors with respect to current social status. For example, parental relationships with their 
children interact to shape those children’s health in adulthood (66) and can inform interventions 
for subsequent generations. Marriage, widowhood, social networks, and social isolation can 
promote or buffer adverse health events, such as depression (67), although the biologic 
mechanisms of these effects are just beginning to be understood (68) Social factors have been 
shown to impact epigenetic age (69), gene expression (70, 71), and telomere length (72, 73), 
suggesting that there are biologic pathways whereby stress may modify aging via biological 
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pathways. These biomarkers may prove useful in judging the effects of social determinant 
interventions to improve health. 
 
Environmental Exposures 
Ecological studies examining the co-occurrence of diseases with environmental monitors (e.g., 
air quality monitors) are rapidly being supplanted by more direct personal exposure assessments. 
Extracellular vesicles, which are membrane-bound nano-vesicles represent a previously hidden 
signaling system that can serve as direct “biosensors” of individual environmental exposures 
(74). Air particulate inhalation and gastrointestinal absorption of toxic metals can be detected 
through the expression of extracellular vesicle-encapsulated microRNAs (75). As a transport and 
signaling mechanism, these vesicles may explain the mechanisms by which environmental 
exposures affect diverse and distant tissues, such as the brain (75). Simultaneously, sophisticated 
mapping of geospatial environments can provide more accurate, direct estimates of personal 
exposures (76) and link these to age-related outcomes (77). New epidemiologic studies should 
also collect more detail on geospatial locations and collect biologic fluids that can be assessed 
for the presence of extracellular vesicles.  
 
While traditional environmental epidemiologic studies have focused on one type of exposure at a 
time (e.g., one single chemical or a class of chemicals), individuals are continuously exposed to 
multiple chemical inputs. To address this, the field has made substantial progress in developing 
both experimental and computational approaches to evaluate the effects of multiple chemicals. 
For instance, new technologies that measure thousands of chemicals simultaneously have 
propelled the concept of the exposome (78)—the environmental equivalent of the genome—that 
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can pair with emerging data approaches to investigate chemical patterns and synergistic effects 
(79). These new methods are ushering in a new era that can help pinpoint the environmental 
drivers of aging with greater accuracy. 
  
Intrinsic Aging 
Aging can be defined as a complex balance between intrinsic and extrinsic damage and repair 
processes. Many of the aforementioned categories of risk are thought to influence the underlying 
biology of aging itself. For example, air pollution might influence aging by its association with 
changes in epigenetic age. The fundamental biologic mechanisms of aging include genomic 
instability, DNA methylation, telomere shortening, proteostasis, cell senescence, mitochondrial 
dysfunction, and stem cell exhaustion (80). These and related mechanisms have been robustly 
linked to aging in cells and animal models but are challenging to measure in free-living humans. 
Changes in these basic biological functions could serve as intermediate biomarkers of aging. 
Epidemiologic studies could be used to develop robust methods in order to characterize these 
changes in humans, determine key external drivers, and assess which methods are most critical 
for measuring key outcomes of interest. Some techniques may be more relevant for specific 
diseases that are strongly age-related, such as some cancers or Alzheimer’s disease, while others 
may be related to fundamental age-related declines in function, such as diminishing gait speed, 
endurance, and muscle strength. Together these aging processes are thought to promote a pro-
inflammatory state and impaired responsiveness to stressors.  Long term cohort studies with 
biological measures can test whether acute or chronic inflammations is associated with aging 
traits (81).  
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Measures of resilience—such as response to exercise or glucose challenge—reveal substantial 
loss of these integrative functions with age, which may reveal changes in an individual long 
before loss of physical function is apparent, thus holding promise as early markers of aging (82, 
83). Studies are underway to evaluate physiologic responses to stressors in clinical settings that 
could be used as probes of age-related multisystem integrity. Several clinically used stress 
tests—such as exercise stress tests, immune responsiveness to vaccines, or blood pressure 
response to cognitive testing—could be evaluated in epidemiologic studies as intermediate 
markers of health span. 
 
Many epidemiologic studies have generated DNA methylation data at one or more time points in 
adulthood, which can be used to further our understanding of the contribution of this key 
epigenetic modification to aging and health span. Widespread DNA methylation changes occur 
with age that are linked to biologic processes (84, 85), and changes in DNA methylation reflect 
lifestyle factors—including obesity (86) and smoking (87)—that could accelerate age-related 
disease progression, while diminishing function. Methylation sites associated with body mass 
index are associated with the expression of lipid metabolism genes. 
 
Epigenetic clocks have been developed utilizing CpG sites that correlate with age in blood (71 
CpGs) or multiple tissues (353 CpGs) (88, 89). These biomarkers of epigenetic age robustly 
predict mortality, have shown some heritability (90), and are associated with some age-related 
diseases. Newer epigenetic biomarkers of aging and phenotypic age can predict health span, 
physical functioning, and Alzheimer’s disease (4). Further, phenotypic DNA methylation age 
associates with several aging pathways, including inflammation, DNA damage response, and 
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mitochondrial function (4). Thus, these CpG sites have strong potential to be utilized in 
explaining the fundamental pathways that drive the processes of aging. Many of these 
methylation sites are highly correlated with chronological and biological aging, and their 
functions are only just beginning to be understood, but it is clear that most of the age-associated 
methylations sites are near transcription factor-binding sites and enhancers (91).  
 
Potentially, DNA methylation could serve as a biomarker in clinical trials that target fundamental 
aging mechanisms. Although the current underlying biology is not clear, methylation clocks have 
been reproducible and sensitive to change in at least one clinical trial (92). 
 
Other indices of biologic age have been calculated in epidemiologic studies using deviations 
from expected values for age of several biomarkers, such as hemoglobin levels, cytokine 
amounts, or physiology, including walking speed or exercise capacity (2-4). Currently, these 
biomarkers have not been clearly linked to underlying aging biology, genetic mechanisms, or 
epigenetic mechanisms, although they have been shown to be sensitive for detecting change over 
time in health dimensions in longitudinal studies with interventions (93, 94). In the future, these 




Designed improvements in longitudinal epidemiologic studies can advance our understanding of 
human aging, its causes, and the related consequences. Previous epidemiologic studies have 
identified and characterized both aging and age-related health outcomes, but only now are we 
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beginning to understand the underlying biology of aging and consider them as potential targets of 
aging in clinical trials. New observational studies are needed to refine assessments regarding the 
lifetime of environmental, lifestyle, and social factors that contribute to an optimal health span. 
These studies can be used to identify earlier intermediate outcomes of aging, such as resilience to 
stressors or biomarkers of early age-related changes. New studies could refine key aspects of 
behavioral factors—including diet, physical activity, and environmental exposures—using 
technologies, such as personal monitoring. Aging is highly heterogeneous in its onset and 
expression. A new generation of studies would give us finer-grained insights that could 
personalize care and management. Some key recommendations are highlighted in Table 1. 
 
Epidemiologic studies are necessary for evaluating if new measures of aging biology are useful 
in defining biologic age, rate of aging, and for assessing the potential magnitude of an 
intervention response. The next generation studies of the epidemiology of aging will need to 
incorporate technological assessments of behavior and environment, which emphasize a robust 
understanding of the biologic processes of aging. These assessments may require special 
imaging, tissues, or cells that are not available in existing biorepositories. Big data cohorts can be 
complemented by smaller, deeply phenotyped cohorts. Routine collection of standardized 
measures of performance and geriatric syndromes and storage of blood specimens from clinical 
care would vastly improve the value of health records for aging research.  
 
Interventions designed to target basic biology of aging mechanisms (geroscience-guided 
therapies) are on the horizon. It is important to underline that while trials targeting the biology of 
aging may include targeted drugs, there is substantial indirect evidence that lifestyle and 
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behavioral modification, as well as the management of environmental factors, may be effective 
in slowing the pace of aging. This theory should be empirically tested, where initial studies could 
focus on very high-risk individuals in whom assessing effectiveness can be performed over a 
limited follow-up. Recent studies have indicated that interventions, including physical activity, 
may be efficacious even very late in life, as very old or sick individuals still show substantial 
responses to intervention and large absolute decreases in risk. Appropriate target populations can 
be best-defined using longitudinal, observational studies, which should include laboratory or 
functional measurements—such as IL-6 levels or gait speed—that can be useful in defining high-
risk individuals for planning interventions.  
 
Outcomes for epidemiologic studies should be designed with an understanding of regulatory 
requirements for clinical trials (95). These can include outcomes reported by clinicians, patients, 
observers, or based on performance, and all outcomes need to be validated based on content, 
reliability, and sensitivity in detecting clinically meaningful changes. Some measures, such as 
gait speed and 6-minute walk test, have been vetted in this manner (53, 96). Health span may be 
the most salient outcome for these intervention trials. When operationalized as a composite of 
accumulated multiple morbidities, health span has been assessed for reliability in epidemiologic 
studies and demonstrated to be sufficiently sensitive to changes for use in clinical trials (40). The 
Aspirin in Reducing Events in the Elderly (ASPREE) trial used disability free survival to define 
health span (97), which was initially operationalized in an epidemiology study (98). While there 
could be other definitions, these two approaches to defining health span have been 
operationalized effectively. 
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Cost and efficiency are major constraints in epidemiologic research. Although some questions 
can be addressed with large clinical or administrative databases, many cannot. Questions 
regarding the impact of medical care and medication can be addressed by utilizing electronic 
health records, while studies that focus on the role of basic biologic mechanisms will likely 
require novel measurements that are rarely used or collected in clinical practice or available in 
existing biobanks. New deep phenotyping studies may be limited in sample size but also can 
serve as platforms for deploying many types of novel assessments. Aging studies that focus on 
midlife or earlier should include very long-term follow-up, at a minimum of 20-30 years. 
Mechanisms to sustain the infrastructure for these types of studies are needed. 
 
Long-term studies are an ideal training environment for scholars new to the aging field. 
Widespread data sharing between institutions has allowed for training programs to use the data 
gathered in these studies to challenge the creative minds of pre- and post-doctoral fellows and 
train the next generation of scientists in the field of aging research. The addition of novel 
measures, assays, and imaging can serve to extend the impact of the studies, providing an 
efficient platform for many career development awards and opportunities for the next generation 
of new investigators. 
 
While the wealth of information collected in previous studies may help address new questions 
about aging, new epidemiological studies that directly apply new models and new measures to 
address the needs of an aging population are required. Novel approaches might include new 
studies of mid-life aging, which may provide information on the early changes in biomarkers and 
physiologic function that emerge early in the pathways to disease and functional decline, as well 
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as follow-up studies of birth cohorts where early life exposures have been well defined. Future 
interventions can be more rapidly deployed by more sharply refocusing epidemiologic studies of 
aging on health span and its potential mechanistic targets.  
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Table 1. Recommendations for future epidemiologic studies of aging 
Recommendation Rationale 
Populations  
Study more recent birth cohorts Physical and social environment has 
changed dramatically 
Continue to follow existing birth to midlife 
cohorts  
Have most efficient time course to study old 
age outcomes 
Include diverse, global populations Aging is advancing most rapidly in minority 
and global populations 
Extend age range to study oldest old Exemplars of health span - 
Underrepresented in past studies 
Use clinically relevant screening and assessment Can use to simulate clinical trial target 
populations 
Assess aging in mid-life Mid-life aging has not been assessed but 
may be ideal point of intervention 
Exposures  
Conduct finer grained assessment of lifestyle 
and behavior with personal monitoring 
Heterogeneity of aging requires more 
personalized approach to therapies 
Include multi-level assessment of environment 
from subcellular to geographic factors 
Environment affects large groups; policy 
change has large impact 
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Evaluate social determinants of health across the 
life course 
Modifiable targets for optimizing health 
span 
Repeat measures over life course  Individual peak and decline are highly 
variable and variability itself may be 
informative 
Anticipate future methods in biologic sample 
preparation, such as extracellular vesicle 
isolation, genomic expression, pluripotent stem 
cells 
Outcomes take many years to develop after 
samples are stored 
Develop biomarkers of aging process that are 
valid and reproducible, including stress response 
and imaging biomarkers 
Can be targets or intermediate outcomes of 
health span-promoting therapies, including 
lifestyle interventions 
Enhance quality of electronic health records for 
aging research 
Exposure and outcome information is 
disease focused, rarely includes function 
Outcomes  
Include self-reported health and quality of life Prioritizes personal values 
Develop common definition of health span Improvement is primary goal of aging 
research 
Use high quality assessments of physical, 
cognitive and psychosocial functioning 
Function summarizes aging process 
Improve methods to assess multimorbidity Composites reflect that most older adults 
have multi co-occurring and interacting 
health conditions 
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Include geriatric syndromes Global, multifactorial syndromes such as 
delerium, falls and frailty are highly 
impactful on function 
  
Synthesis  
Consider heterogeneity, bias and competing risk Given challenges of aging research 
Set standards for machine learning approaches Lack of transparency challenges 
interpretation 
Use systems approach Needed to capture the complexity of aging 
processes 
 
Accepted for publication – 09/25/19. May not be duplicated or reproduced without permission of the 





1. Chatterji S, Byles J, Cutler D, Seeman T, Verdes E. Health, functioning, and disability in older 
adults--present status and future implications. Lancet. 2015;385:563-575. 10.1016/S0140-
6736(14)61462-8. 
2. Belsky DW, Caspi A, Houts R, Cohen HJ, Corcoran DL, Danese A, et al. Quantification of biological 
aging in young adults. Proceedings of the National Academy of Sciences of the United States of America. 
2015;112:E4104-4110. 10.1073/pnas.1506264112. 
3. Sanders JL, Arnold AM, Boudreau RM, Hirsch CH, Kizer JR, Kaplan RC, et al. Association of 
Biomarker and Physiologic Indices With Mortality in Older Adults: Cardiovascular Health Study. The 
Journals of Gerontology: Series A. 2018;74:114-120. 10.1093/gerona/gly075. 
4. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An epigenetic biomarker of 
aging for lifespan and healthspan. Aging. 2018;10:573-591. 10.18632/aging.101414. 
5. Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: conceptual 
models, empirical challenges and interdisciplinary perspectives. International journal of epidemiology. 
2002;31:285-293.  
6. Ben-Shlomo Y, Cooper R, Kuh D. The last two decades of life course epidemiology, and its 
relevance for research on ageing. International journal of epidemiology. 2016;45:973-988. 
10.1093/ije/dyw096. 
7. Crawford JR, Deary IJ, Starr J, Whalley LJ. The NART as an index of prior intellectual functioning: 
A retrospective validity study covering a 66-year interval. Psychological Medicine. 2001;31:451-458. 
10.1017/S0033291701003634. 
8. Elo IT, Mykyta L, Sebastiani P, Christensen K, Glynn NW, Perls T. Age validation in the long life 
family study through a linkage to early-life census records. The journals of gerontology Series B, 
Psychological sciences and social sciences. 2013;68:580-585. 10.1093/geronb/gbt033. 
9. Murray ET, Ben-Shlomo Y, Tilling K, Southall H, Aucott P, Kuh D, et al. Area deprivation across 
the life course and physical capability in midlife: findings from the 1946 British Birth cohort. American 
journal of epidemiology. 2013;178:441-450. 10.1093/aje/kwt003. 
10. Dodds RM, Syddall HE, Cooper R, Benzeval M, Deary IJ, Dennison EM, et al. Grip strength across 
the life course: normative data from twelve British studies. PloS one. 2014;9:e113637. 
10.1371/journal.pone.0113637. 
11. Nguyen TT, Tchetgen Tchetgen EJ, Kawachi I, Gilman SE, Walter S, Liu SY, et al. Instrumental 
variable approaches to identifying the causal effect of educational attainment on dementia risk. Annals 
of epidemiology. 2016;26:71-76.e71-73. 10.1016/j.annepidem.2015.10.006. 
12. Breeze E, Clarke R, Shipley MJ, Marmot MG, Fletcher AE. Cause-specific mortality in old age in 
relation to body mass index in middle age and in old age: follow-up of the Whitehall cohort of male civil 
servants. International journal of epidemiology. 2006;35:169-178. 10.1093/ije/dyi212. 
13. Liu K, Colangelo LA, Daviglus ML, Goff DC, Pletcher M, Schreiner PJ, et al. Can Antihypertensive 
Treatment Restore the Risk of Cardiovascular Disease to Ideal Levels?: The Coronary Artery Risk 
Development in Young Adults (CARDIA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA). 
Journal of the American Heart Association. 2015;4:e002275. 10.1161/jaha.115.002275. 
14. Bowman K, Jones L, Pilling LC, Delgado J, Kuchel GA, Ferrucci L, et al. Vitamin D levels and risk of 
delirium. A mendelian randomization study in the UK Biobank. 
2019;10.1212/wnl.0000000000007136:10.1212/WNL.0000000000007136. 
10.1212/wnl.0000000000007136. 
Accepted for publication – 09/25/19. May not be duplicated or reproduced without permission of the 
Journal of Gerontology: Medical Sciences.   
32 
 
15. Hustad E, Skogholt AH, Hveem K, Aasly JO. The accuracy of the clinical diagnosis of Parkinson 
disease. The HUNT study. Journal of neurology. 2018;265:2120-2124. 10.1007/s00415-018-8969-6. 
16. Bowman K, Thambisetty M, Kuchel GA, Ferrucci L, Melzer D. Obesity and Longer Term Risks of 
Dementia in 65-74 Year Olds. Age and ageing. 2019;10.1093/ageing/afz002. 10.1093/ageing/afz002. 
17. Walker VM, Davies NM, Windmeijer F, Burgess S, Martin RM. Power calculator for instrumental 
variable analysis in pharmacoepidemiology. International journal of epidemiology. 2017;46:1627-1632. 
10.1093/ije/dyx090. 
18. Tamosauskaite J, Atkins JL, Pilling LC, Kuo C-L, Kuchel GA, Ferrucci L, et al. Hereditary 
Hemochromatosis Associations with Frailty, Sarcopenia and Chronic Pain: Evidence from 200,975 Older 
UK Biobank Participants. The Journals of Gerontology: Series A. 2019;74:337-342. 
10.1093/gerona/gly270. 
19. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of 
Hypertension in Patients 80 Years of Age or Older. New England Journal of Medicine. 2008;358:1887-
1898. 10.1056/NEJMoa0801369. 
20. Donaghy PC, O'Brien JT, Thomas AJ. Prodromal dementia with Lewy bodies. Psychol Med. 
2015;45:259-268. 10.1017/S0033291714000816. 
21. Urbanelli L, Buratta S, Sagini K, Tancini B, Emiliani C. Extracellular Vesicles as New Players in 
Cellular Senescence. Int J Mol Sci. 2016;17. 10.3390/ijms17091408. 
22. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, et al. mTOR 
inhibition improves immune function in the elderly. Science Translational Medicine. 2014;6:268ra179-
268ra179. 10.1126/scitranslmed.3009892. 
23. Espinoza SE, Musi N, Wang CP, Michalek J, Orsak B, Romo T, et al. Rationale and Study Design of 
a Randomized Clinical Trial of Metformin to Prevent Frailty in Older Adults with Pre-Diabetes. The 
journals of gerontology Series A, Biological sciences and medical sciences. 2019;10.1093/gerona/glz078. 
10.1093/gerona/glz078. 
24. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. 
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England journal of 
medicine. 2017;377:1119-1131. 10.1056/NEJMoa1707914. 
25. Kraus WE, Bhapkar M, Huffman KM, Pieper CF, Krupa Das S, Redman LM, et al. 2 years of calorie 
restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, 
randomised controlled trial. The lancet Diabetes & endocrinology. 2019;10.1016/s2213-8587(19)30151-
2. 10.1016/s2213-8587(19)30151-2. 
26. Guralnik JM, Kritchevsky SB. Translating research to promote healthy aging: the complementary 
role of longitudinal studies and clinical trials. Journal of the American Geriatrics Society. 2010;58 Suppl 
2:S337-342. 10.1111/j.1532-5415.2010.02938.x. 
27. Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, Castelli WP. Systolic blood pressure, 
arterial rigidity, and risk of stroke. The Framingham study. Jama. 1981;245:1225-1229.  
28. Shekelle R, Ostfeld A, Klawans HJ. Prevention of stroke by antihypertensive drug treatment in 
older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly 
Program (SHEP). SHEP Cooperative Research Group. Jama. 1991;265:3255-3264.  
29. Di Bari M, Pahor M, Franse LV, Shorr RI, Wan JY, Ferrucci L, et al. Dementia and disability 
outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly 
program (SHEP) trial. American journal of epidemiology. 2001;153:72-78.  
30. Pahor M, Guralnik JM, Ambrosius WT, Blair S, Bonds DE, Church TS, et al. Effect of structured 
physical activity on prevention of major mobility disability in older adults: the LIFE study randomized 
clinical trial. Jama. 2014;311:2387-2396. 10.1001/jama.2014.5616. 
Accepted for publication – 09/25/19. May not be duplicated or reproduced without permission of the 
Journal of Gerontology: Medical Sciences.   
33 
 
31. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in 
persons over the age of 70 years as a predictor of subsequent disability. The New England journal of 
medicine. 1995;332:556-561. 10.1056/nejm199503023320902. 
32. Pahor M GJ, Anton SD, Ambrosius WT, Blair SN, Church TS, Espeland MA, Fielding RA, Gill TM, 
Glynn NW, Groessl EJ, King AC, Kritchevsky SB, Manini TM, McDermott MM, Miller ME, Newman AB, 
Williamson JD. Impact and lessons learned from the LIFE Studies. Journal of American Geriatric Society. 
2019.  
33. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, 
instability, and episodic hypertension. Lancet. 2010;375:938-948. 10.1016/S0140-6736(10)60309-1. 
34. Bernard MA, Clayton JA, Lauer MS. Inclusion Across the Lifespan: NIH Policy for Clinical 
ResearchNIH Policy for Inclusion Across the Lifespan in Clinical ResearchNIH Policy for Inclusion Across 
the Lifespan in Clinical Research. JAMA. 2018;320:1535-1536. 10.1001/jama.2018.12368. 
35. Kuchel GA. Inclusion of Older Adults in Research: Ensuring Relevance, Feasibility, and Rigor. 
Journal of the American Geriatrics Society. 2019;67:203-204. 10.1111/jgs.15802. 
36. Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: A new era in 
clinical research. Perspectives in clinical research. 2011;2:137-144. 10.4103/2229-3485.86879. 
37. Boyd CM, Fortin M. Future of Multimorbidity Research: How Should Understanding of 
Multimorbidity Inform Health System Design? Public Health Reviews. 2010;32:451-474. 
10.1007/bf03391611. 
38. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes care. 
2006;29:725-731. https://doi.org/10.2337/diacare.29.03.06.dc05-2078 
39. Tisminetzky M, Bayliss EA, Magaziner JS, Allore HG, Anzuoni K, Boyd CM, et al. Research 
Priorities to Advance the Health and Health Care of Older Adults with Multiple Chronic Conditions. 
Journal of the American Geriatrics Society. 2017;65:1549-1553. 10.1111/jgs.14943. 
40. Espeland MA, Crimmins EM, Grossardt BR, Crandall JP, Gelfond JA, Harris TB, et al. Clinical Trials 
Targeting Aging and Age-Related Multimorbidity. The journals of gerontology Series A, Biological 
sciences and medical sciences. 2017;72:355-361. 10.1093/gerona/glw220. 
41. Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy 
implications of a core geriatric concept. Journal of the American Geriatrics Society. 2007;55:780-791. 
10.1111/j.1532-5415.2007.01156.x. 
42. Bartley JM, Pan SJ, Keilich SR, Hopkins JW, Al-Naggar IM, Kuchel GA, et al. Aging augments the 
impact of influenza respiratory tract infection on mobility impairments, muscle-localized inflammation, 
and muscle atrophy. Aging. 2016;8:620-635. 10.18632/aging.100882. 
43. Rudolph JL, Doherty K, Kelly B, Driver JA, Archambault E. Validation of a Delirium Risk 
Assessment Using Electronic Medical Record Information. Journal of the American Medical Directors 
Association. 2016;17:244-248. 10.1016/j.jamda.2015.10.020. 
44. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. [Review][Erratum 
appears in Lancet. 2013 Oct 19;382(9901):1328]. Lancet. 2013;381:752-762.  
45. Walston J, Bandeen-Roche K, Buta B, Bergman H, Gill TM, Morley JE, et al. Moving Frailty 
Toward Clinical Practice: NIA Intramural Frailty Science Symposium Summary. Journal of the American 
Geriatrics Society. 2019;67:1559-1564. 10.1111/jgs.15928. 
46. Puts MTE, Toubasi S, Andrew MK, Ashe MC, Ploeg J, Atkinson E, et al. Interventions to prevent 
or reduce the level of frailty in community-dwelling older adults: a scoping review of the literature and 
international policies. Age and ageing. 2017;46:383-392. 10.1093/ageing/afw247. 
47. Buta BJ, Walston JD, Godino JG, Park M, Kalyani RR, Xue QL, et al. Frailty assessment 
instruments: Systematic characterization of the uses and contexts of highly-cited instruments. Ageing 
research reviews. 2016;26:53-61. 10.1016/j.arr.2015.12.003. 
Accepted for publication – 09/25/19. May not be duplicated or reproduced without permission of the 
Journal of Gerontology: Medical Sciences.   
34 
 
48. Freedman VA, Wolf DA, Spillman BC. Disability-Free Life Expectancy Over 30 Years: A Growing 
Female Disadvantage in the US Population. American journal of public health. 2016;106:1079-1085. 
10.2105/ajph.2016.303089. 
49. Freedman VA. Adopting the ICF language for studying late-life disability: a field of dreams? The 
journals of gerontology Series A, Biological sciences and medical sciences. 2009;64:1172-1174; 
discussion 1175-1176. 10.1093/gerona/glp095. 
50. Jacob ME, Marron MM, Boudreau RM, Odden MC, Arnold AM, Newman AB. Age, Race, and 
Gender Factors in Incident Disability. The journals of gerontology Series A, Biological sciences and 
medical sciences. 2018;73:194-197. 10.1093/gerona/glx194. 
51. Stolz E, Gill TM, Mayerl H, Freidl W. Short-Term Disability Fluctuations in Late Life. The Journals 
of Gerontology: Series B. 2019;10.1093/geronb/gbz089. 10.1093/geronb/gbz089. 
52. Pahor M, Anton SD, Beavers DP, Cauley JA, Fielding RA, Kritchevsky SB, et al. Effect of losartan 
and fish oil on plasma IL-6 and mobility in older persons. The ENRGISE Pilot randomized clinical trial. The 
journals of gerontology Series A, Biological sciences and medical sciences. 2018;10.1093/gerona/gly277. 
10.1093/gerona/gly277. 
53. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in 
common physical performance measures in older adults. Journal of the American Geriatrics Society. 
2006;54:743-749. 10.1111/j.1532-5415.2006.00701.x. 
54. Ainsworth B, Cahalin L, Buman M, Ross R. The current state of physical activity assessment tools. 
Progress in cardiovascular diseases. 2015;57:387-395. 10.1016/j.pcad.2014.10.005. 
55. Schrack JA, Zipunnikov V, Goldsmith J, Bai J, Simonsick EM, Crainiceanu C, et al. Assessing the 
"physical cliff": detailed quantification of age-related differences in daily patterns of physical activity. 
The journals of gerontology Series A, Biological sciences and medical sciences. 2014;69:973-979. 
10.1093/gerona/glt199. 
56. Nastasi AJ, Ahuja A, Zipunnikov V, Simonsick EM, Ferrucci L, Schrack JA. Objectively Measured 
Physical Activity and Falls in Well-Functioning Older Adults: Findings From the Baltimore Longitudinal 
Study of Aging. American journal of physical medicine & rehabilitation. 2018;97:255-260. 
10.1097/phm.0000000000000830. 
57. Schrack JA, Kuo PL, Wanigatunga AA, Di J, Simonsick EM, Spira AP, et al. Active-to-Sedentary 
Behavior Transitions, Fatigability, and Physical Functioning in Older Adults. The journals of gerontology 
Series A, Biological sciences and medical sciences. 2018;10.1093/gerona/gly243. 
10.1093/gerona/gly243. 
58. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal 
vitamin D status. Osteoporos Int. 2005;16:713-716. 10.1007/s00198-005-1867-7. 
59. Rebholz CM, Zheng Z, Grams ME, Appel LJ, Sarnak MJ, Inker LA, et al. Serum metabolites 
associated with dietary protein intake: results from the Modification of Diet in Renal Disease (MDRD) 
randomized clinical trial. Am J Clin Nutr. 2019;109:517-525. 10.1093/ajcn/nqy202. 
60. Almanza-Aguilera E, Urpi-Sarda M, Llorach R, Vazquez-Fresno R, Garcia-Aloy M, Carmona F, et al. 
Microbial metabolites are associated with a high adherence to a Mediterranean dietary pattern using a 
(1)H-NMR-based untargeted metabolomics approach. The Journal of nutritional biochemistry. 
2017;48:36-43. 10.1016/j.jnutbio.2017.06.001. 
61. Guasch-Ferré M, Bhupathiraju SN, Hu FB. Use of Metabolomics in Improving Assessment of 
Dietary Intake. Clinical Chemistry. 2018;64:82-98. 10.1373/clinchem.2017.272344. 
62. Jin Q, Black A, Kales SN, Vattem D, Ruiz-Canela M, Sotos-Prieto M. Metabolomics and 
Microbiomes as Potential Tools to Evaluate the Effects of the Mediterranean Diet. Nutrients. 2019;11. 
10.3390/nu11010207. 
63. McCullough ML. Dietary assessment in the digital age: the ongoing quest for better methods. 
Am J Clin Nutr. 2018;107:1-2. 10.1093/ajcn/nqx066. 
Accepted for publication – 09/25/19. May not be duplicated or reproduced without permission of the 
Journal of Gerontology: Medical Sciences.   
35 
 
64. Hu FB, Willett WC. Current and Future Landscape of Nutritional Epidemiologic Research. Jama. 
2018;320:2073-2074. 10.1001/jama.2018.16166. 
65. Birnie K, Cooper R, Martin RM, Kuh D, Sayer AA, Alvarado BE, et al. Childhood socioeconomic 
position and objectively measured physical capability levels in adulthood: a systematic review and meta-
analysis. PLoS One. 2011;6:e15564. 10.1371/journal.pone.0015564. 
66. Andersson MA. Chronic Disease at Midlife: Do Parent-child Bonds Modify the Effect of 
Childhood SES? Journal of health and social behavior. 2016;57:373-389. 10.1177/0022146516661596. 
67. Jadhav A, Weir D. Widowhood and Depression in a Cross-National Perspective: Evidence from 
the United States, Europe, Korea, and China. The journals of gerontology Series B, Psychological sciences 
and social sciences. 2018;73:e143-e153. 10.1093/geronb/gbx021. 
68. Bennett-Britton I, Teyhan A, Macleod J, Sattar N, Davey Smith G, Ben-Shlomo Y. Changes in 
marital quality over 6 years and its association with cardiovascular disease risk factors in men: findings 
from the ALSPAC prospective cohort study. J Epidemiol Community Health. 2017;71:1094-1100. 
10.1136/jech-2017-209178. 
69. Hughes A, Smart M, Gorrie-Stone T, Hannon E, Mill J, Bao Y, et al. Socioeconomic Position and 
DNA Methylation Age Acceleration Across the Life Course. American journal of epidemiology. 
2018;187:2346-2354. 10.1093/aje/kwy155. 
70. Levine ME, Crimmins EM, Weir DR, Cole SW. Contemporaneous Social Environment and the 
Architecture of Late-Life Gene Expression Profiles. American journal of epidemiology. 2017;186:503-509. 
10.1093/aje/kwx147. 
71. Cole SW, Capitanio JP, Chun K, Arevalo JMG, Ma J, Cacioppo JT. Myeloid differentiation 
architecture of leukocyte transcriptome dynamics in perceived social isolation. Proceedings of the 
National Academy of Sciences. 2015;112:15142-15147. 10.1073/pnas.1514249112. 
72. Price LH, Kao H-T, Burgers DE, Carpenter LL, Tyrka AR. Telomeres and Early-Life Stress: An 
Overview. Biological Psychiatry. 2013;73:15-23. https://doi.org/10.1016/j.biopsych.2012.06.025. 
73. Puterman E, Gemmill A, Karasek D, Weir D, Adler NE, Prather AA, et al. Lifespan adversity and 
later adulthood telomere length in the nationally representative US Health and Retirement Study. 
Proceedings of the National Academy of Sciences of the United States of America. 2016;113:E6335-
e6342. 10.1073/pnas.1525602113. 
74. Machtinger R, Bollati V, Baccarelli AA. Chapter 3-2 - miRNAs and lncRNAs as Biomarkers of 
Toxicant Exposure. In: McCullough SD, Dolinoy DC, eds. Toxicoepigenetics. Academic Press; 2019:237-
247. https://doi.org/10.1016/B978-0-12-812433-8.00010-1. 
75. Bollati V, Angelici L, Rizzo G, Pergoli L, Rota F, Hoxha M, et al. Microvesicle-associated microRNA 
expression is altered upon particulate matter exposure in healthy workers and in A549 cells. Journal of 
Applied Toxicology. 2015;35:59-67. doi:10.1002/jat.2987. 
76. Nwanaji-Enwerem JC, Colicino E, Trevisi L, Kloog I, Just AC, Shen J, et al. Long-term ambient 
particle exposures and blood DNA methylation age: findings from the VA normative aging study. 
Environmental Epigenetics. 2016;2. 10.1093/eep/dvw006. 
77. Cacciottolo M, Wang X, Driscoll I, Woodward N, Saffari A, Reyes J, et al. Particulate air 
pollutants, APOE alleles and their contributions to cognitive impairment in older women and to 
amyloidogenesis in experimental models. Translational psychiatry. 2017;7:e1022. 10.1038/tp.2016.280. 
78. Niedzwiecki MM, Walker DI, Vermeulen R, Chadeau-Hyam M, Jones DP, Miller GW. The 
Exposome: Molecules to Populations. Annual review of pharmacology and toxicology. 2019;59:107-127. 
10.1146/annurev-pharmtox-010818-021315. 
79. Gibson EA, Goldsmith J, Kioumourtzoglou MA. Complex Mixtures, Complex Analyses: an 
Emphasis on Interpretable Results. Current environmental health reports. 2019;6:53-61. 
10.1007/s40572-019-00229-5. 
Accepted for publication – 09/25/19. May not be duplicated or reproduced without permission of the 
Journal of Gerontology: Medical Sciences.   
36 
 
80. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 
2013;153:1194-1217. 10.1016/j.cell.2013.05.039. 
81. Kuh D, Cooper R, Sattar N, Welsh P, Hardy R, Ben-Shlomo Y. Systemic Inflammation and Cardio-
Renal Organ Damage Biomarkers in Middle Age Are Associated With Physical Capability Up to 9 Years 
Later. Circulation. 2019;139:1988-1999. 10.1161/CIRCULATIONAHA.118.037332. 
82. Kirkland JL, Stout MB, Sierra F. Resilience in Aging Mice. The journals of gerontology Series A, 
Biological sciences and medical sciences. 2016;71:1407-1414. 10.1093/gerona/glw086. 
83. Hadley EC, Kuchel GA, Newman AB. Report: NIA Workshop on Measures of Physiologic 
Resiliencies in Human Aging. The journals of gerontology Series A, Biological sciences and medical 
sciences. 2017;72:980-990. 10.1093/gerona/glx015. 
84. Bell JT, Tsai PC, Yang TP, Pidsley R, Nisbet J, Glass D, et al. Epigenome-wide scans identify 
differentially methylated regions for age and age-related phenotypes in a healthy ageing population. 
PLoS genetics. 2012;8:e1002629. 10.1371/journal.pgen.1002629. 
85. Alisch RS, Barwick BG, Chopra P, Myrick LK, Satten GA, Conneely KN, et al. Age-associated DNA 
methylation in pediatric populations. Genome research. 2012;22:623-632. 10.1101/gr.125187.111. 
86. Mendelson MM, Marioni RE, Joehanes R, Liu C, Hedman AK, Aslibekyan S, et al. Association of 
Body Mass Index with DNA Methylation and Gene Expression in Blood Cells and Relations to 
Cardiometabolic Disease: A Mendelian Randomization Approach. PLoS medicine. 2017;14:e1002215. 
10.1371/journal.pmed.1002215. 
87. Joehanes R, Just AC, Marioni RE, Pilling LC, Reynolds LM, Mandaviya PR, et al. Epigenetic 
Signatures of Cigarette Smoking. Circulation Cardiovascular genetics. 2016;9:436-447. 
10.1161/circgenetics.116.001506. 
88. Horvath S. DNA methylation age of human tissues and cell types. Genome biology. 
2013;14:R115. 10.1186/gb-2013-14-10-r115. 
89. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, et al. Genome-wide methylation 
profiles reveal quantitative views of human aging rates. Molecular cell. 2013;49:359-367. 
10.1016/j.molcel.2012.10.016. 
90. Robins C, McRae AF, Powell JE, Wiener HW, Aslibekyan S, Kennedy EM, et al. Testing Two 
Evolutionary Theories of Human Aging with DNA Methylation Data. Genetics. 2017;207:1547-1560. 
10.1534/genetics.117.300217. 
91. Bell CG, Xia Y, Yuan W, Gao F, Ward K, Roos L, et al. Novel regional age-associated DNA 
methylation changes within human common disease-associated loci. Genome biology. 2016;17:193. 
10.1186/s13059-016-1051-8. 
92. Chen L, Dong Y, Bhagatwala J, Raed A, Huang Y, Zhu H. Effects of Vitamin D3 Supplementation 
on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A 
Randomized Clinical Trial. The Journals of Gerontology: Series A. 2018;74:91-98. 10.1093/gerona/gly223. 
93. Belsky DW, Huffman KM, Pieper CF, Shalev I, Kraus WE. Change in the Rate of Biological Aging in 
Response to Caloric Restriction: CALERIE Biobank Analysis. The Journals of Gerontology: Series A. 
2017;73:4-10. 10.1093/gerona/glx096. 
94. O'Connell MDL, Marron MM, Boudreau RM, Canney M, Sanders JL, Kenny RA, et al. Mortality in 
Relation to Changes in a Healthy Aging Index: The Health, Aging and Body Composition Study. The 
journals of gerontology Series A, Biological sciences and medical sciences. 2018;10.1093/gerona/gly114. 
10.1093/gerona/gly114. 
95. Zarin DA, Tse T, Williams RJ, Carr S. Trial Reporting in ClinicalTrials.gov — The Final Rule. New 
England Journal of Medicine. 2016;375:1998-2004. 10.1056/NEJMsr1611785. 
96. Bohannon RW, Crouch R. Minimal clinically important difference for change in 6-minute walk 
test distance of adults with pathology: a systematic review. Journal of evaluation in clinical practice. 
2017;23:377-381. 10.1111/jep.12629. 
Accepted for publication – 09/25/19. May not be duplicated or reproduced without permission of the 
Journal of Gerontology: Medical Sciences.   
37 
 
97. McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, et al. Effect of Aspirin on 
Disability-free Survival in the Healthy Elderly. The New England journal of medicine. 2018;379:1499-
1508. 10.1056/NEJMoa1800722. 
98. Jacob ME, Yee LM, Diehr PH, Arnold AM, Thielke SM, Chaves PH, et al. Can a Healthy Lifestyle 




Accepted for publication – 09/25/19. May not be duplicated or reproduced without permission of the 
Journal of Gerontology: Medical Sciences.   
38 
 
Figure 1. 
 
